Evidence map›Paper›PMID 31240576›Full record

ArticleClinical drug investigation2019

Drug-Drug Interactions in Children and Adolescents Receiving Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C Virus Infection.

Hala Mohsen Abdullatif, Rania Ramzi, Engy Adel Mogahed, Carolyne Morcos Ghobrial, Basma Abd El Rasheed Abd El Zaher, Mona S El Raziky, Hanaa Mostafa El-Karaksy

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical drug investigation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hala Mohsen AbdullatifPediatric Hepatology Unit, Cairo University Pediatric Hospital, El Saray Street, El Manial, Cairo, 11956, Egypt. halamohsen@kasralainy.edu.eg.ORCID http://orcid.org/0000-0002-2398-5231
Rania RamziKasr Alainy Drug Information Center, Cairo University, Cairo, Egypt.
Engy Adel MogahedPediatric Hepatology Unit, Cairo University Pediatric Hospital, El Saray Street, El Manial, Cairo, 11956, Egypt.
Carolyne Morcos GhobrialPediatric Hepatology Unit, Cairo University Pediatric Hospital, El Saray Street, El Manial, Cairo, 11956, Egypt.
Basma Abd El Rasheed Abd El ZaherKasr Alainy Drug Information Center, Cairo University, Cairo, Egypt.
Mona S El RazikyPediatric Hepatology Unit, Cairo University Pediatric Hospital, El Saray Street, El Manial, Cairo, 11956, Egypt.
Hanaa Mostafa El-KaraksyPediatric Hepatology Unit, Cairo University Pediatric Hospital, El Saray Street, El Manial, Cairo, 11956, Egypt.
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveDrug-drug interactions need to be considered to optimize the pharmacotherapeutic outcome of direct-acting antivirals. The aim of this study was to report on possible drug-drug interactions between ledipasvir/sofosbuvir and other medications received by children and adolescents with hepatitis C virus, in addition to suggested management for these drug-drug interactions.

methodsHepatitis C virus-infected children and adolescents, 12-17 years of age and/or weighing ≥ 35 kg, who presented to the Pediatric Hepatology Unit at Cairo University Pediatric Hospitals for ledipasvir/sofosbuvir treatment were included. Medication history was taken including long-term medications for chronic conditions and on-demand medications for inter-current illnesses. Medications were reviewed by the Kasr Alainy Drug Information Center to identify possible drug-drug interactions with prescribed ledipasvir/sofosbuvir and their management. HEP Drug Interactions provided by the University of Liverpool, Lexicomp

resultsSixty hepatitis C virus-infected children and adolescents assigned to receive ledipasvir/sofosbuvir were enrolled. Thirty percent of patients had associated chronic co-morbid conditions. The overall number of medications received was 48; 39 were prescribed as long-term medications with a median of 3 (interquartile range 4.24) medications per patient. Proton pump inhibitors, antacids, histamine H

conclusionsEarly identification and prompt response to drug-drug interactions with the aid of pharmacists optimize the pharmacotherapeutic outcome and eliminate possible morbidities when using direct-acting antivirals in children and adolescents with hepatitis C virus.

Indexed as

AdolescentAntiviral AgentsBenzimidazolesChildDrug InteractionsFemaleFluorenesHepatitis CHepatitis C, ChronicHumansMaleRisk AssessmentSofosbuvirTreatment OutcomeUridine MonophosphateAntiviral AgentsBenzimidazolesFluorenesledipasvir, sofosbuvir drug combinationSofosbuvirUridine Monophosphate

Identifiers

PMID31240576
OpenAlexW2954004369

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.